Sign In
Learn bits
Health & Medicine
Mahesh

08/03/24 12:14 PM IST

India to restart Penicillin G manufacture

In News
  • India will start manufacturing the common antibiotic Penicillin G later this year, three decades after the country’s last plant shut down.
Why it was stopped?
  • Penicillin G, just like many other APIs that India manufactured, was phased out of production because of subsidy-driven cheaper Chinese products flooding the market.
  • The last plant to stop production of the antibiotic was of Torrent Pharma in Ahmedabad.
  • There were at least five companies, including Torrent, which manufactured Penicillin G in the country in the 90s.
  • But the prices of the Chinese products were so low that the Indian manufacturers went out of business.
  • The huge plants had to be sold for scrap.
  • There were nearly 2,000 API manufacturers in India in the early 90s.
  • But there were nearly 10,000 units that manufactured formulations. And, for them, the cheaper Chinese products made more sense, especially at a time when the country’s economy was opening up and customs rules were relaxed.
  • The Drug Prices Control Order — which capped prices of essential medicines — also ensured that more companies went for cheaper imported products.
  • The production of Penicillin will be restarted by mid-2024 by Hyderabad-based Aurobindo pharma.
Reasons to restart
  • One, the need wasn’t felt. “While the industry and government were aware of the decline in production of APIs in India, as cheaper alternatives were available in the globalised world, there wasn’t much focus on restarting production within the country.
  • The supply chain disruption caused during the pandemic was a wake-up call that we needed to be self-reliant.
  • This led to the government launching the PLI scheme to support manufacturing within the country.
  • Two, there are huge initial costs. “Manufacturing an API, especially a fermented one like Penicillin G, is cost-intensive. There is huge capital expenditure involved in setting up a factory, with the company being able to break even only after a couple of years,” said the first expert.
  • Third, China is already a well-established supplier. “Our neighbour has scaled up manufacturing several-folds in the last three decades. Competing with the prices would require investments in bigger facilities.
Impact of PLI schemes
  • There has been a decline in imports of APIs since the launch of the PLI scheme.
  • There has been a decline in the imports of APIs. Take the example of paracetamol — before the pandemic, we were importing two-thirds of the API needed, now that volume has halved.
  • The scheme envisages a support of 20% for first four years, 15% for fifth year, and 5% for sixth year on eligible sales of fermentation-based bulk drugs such as antibiotics, enzymes, and hormones such as insulin.
  • These are more difficult to manufacture, with fermentation used to cultivate micro-organisms for the synthesis of the drugs.
  • For chemically synthesised drugs, the incentive will be at the rate of 10% for six years on eligible sales.
Source- Indian Express

More Related Current Affairs View All

15 Nov

Government issues guidelines to curb misleading ads by coaching centres

'The central Government issued new guidelines aimed at curbing misleading advertisements by coaching institutes, specifically prohibiting false promises such as "100 per cent selec

Read More

15 Nov

Janjatiya Gaurav Divas

'Every year on November 15th, Janjatiya Gaurav Divas is celebrated to honor the contributions of these communities, especially in India’s freedom struggle.' 5th November

Read More

15 Nov

Supreme Court’s order on mandatory accessibility standards

'A bench of the Supreme Court last week ordered the Union government to frame mandatory rules for ensuring the accessibility of public places and services to persons with disabilit

Read More

India’s First Ai-Driven Magazine Generator

Generate Your Custom Current Affairs Magazine using our AI in just 3 steps